SEC 13F Intelligence

Trails Edge Capital Partners, LP / FDMT

Trails Edge Capital Partners, LP’s 4d Molecular Therapeutics In Position

Does Trails Edge Capital Partners, LP own 4d Molecular Therapeutics In (FDMT)? Yes1.30M shares worth $12M (+2.78% of its 13F portfolio) as of Q1 2026.

Position Value
$12M
Q1 2026
Shares
1.30M
% of Portfolio
+2.78%
Quarters Held
1
currently held

Position History FDMT

Reported value by quarter
Q1 ’26: $12MQ1 ’26filingsflow.com
QuarterSharesValue% of Portfolio
Q1 20261.30M$12M+2.78%

Common-stock position only; options are excluded. Quarters where the fund filed no 13F or reported no position are absent. See Trails Edge Capital Partners, LP’s full portfolio or all institutional holders of FDMT.